Cybin has successfully demonstrated proof of concept for two new drug candidates in internal testing as it moves toward IND status.
Cybin has successfully demonstrated proof of concept for two new drug candidates in internal testing as it moves toward IND status.
LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback
Low share prices. VERY low trading volumes. The slump in psychedelic stocks in 2021 looks a lot like the slump in 2020.
Cybin adds several experts in mental health to its Clinical Advisory Board.
Digital therapeutics is the wave of the future in healthcare. The psychedelic drug industry is at the forefront for this new tech.
Novamind increases its strategic investment in Bionomics Limited, in support of its plans for a Phase IIb clinical trial for PTSD.
A New England Journal of Medicine study found CMPS's COMP360 psilocybin therapy performed better than the leading antidepressant.
Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience And Will Help To Drive MINDCURE’s Commercial Focus And Strategic Partnerships
A recent study shows HALF of all adults already experiencing anxiety due to the social isolation from COVID-19 lockdowns. COVID Isolation Syndrome.
Ireland-based GH Research has just raised $125 million in an oversubscribed Series B financing round.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now